How do pharmaceutical companies “defend” a brand when exclusivity loss is approaching?
Companies typically try to extend a brand’s commercial life by shifting some share of the market to newer or expanded uses, and by protecting the product’s legal and regulatory position. The “lifecycle management” moves most often fall into two buckets: expanding label indications (so the brand can serve more patients) and maintaining regulatory or patent/regulatory exclusivity for existing uses.
Label expansion is one of the most common defenses because it can keep the product relevant for prescribers and patients even as generic competition starts for older indications.
What does “lifecycle management” mean in practice around loss of exclusivity?
Lifecycle management is the set of actions a manufacturer takes to slow revenue decline after initial exclusivity ends. When the immediate threat is generic entry, label expansion is frequently paired with evidence-generation (new trials or new analyses) that supports additional indications, patient subgroups, dosing strategies, or combinations. That creates new prescribing demand and can improve payer coverage for broader or newly eligible patients.
How does label expansion work as a strategy during generic pressure?
Label expansion can do three things during the run-up to generic competition:
1. Adds new eligible patient groups or clinical settings
More diagnoses, stages of disease, or treatment lines can qualify patients for the brand.
2. Improves positioning versus competitors
When a brand receives a broader label, clinicians may view it as a default option for a larger population, not just for the narrow indication that is about to be competed.
3. Sustains contracting and reimbursement relevance
Payers often update formularies and coverage rules around the active labeled uses. New labeled indications can help maintain formulary access.
Which kind of evidence supports “label expansion”?
Label expansions generally rely on clinical trial data sufficient for regulators to determine that the new use is effective and safe. Companies may seek label expansion for:
- New indications (a different disease or population)
- Expanded age or severity groups
- New combination regimens or dosing schedules
- Additional endpoints or subgroup findings that support the broader use
The exact pathway depends on the regulator and the existing product dossier.
Is label expansion always enough to stop the revenue drop?
Not always. Generic entry can still rapidly erode sales for the original indication, even if new indications launch. The impact depends on how large the incremental market is, how quickly the new label is adopted by clinicians, and whether payers cover the expanded uses competitively.
In many cases, label expansion helps, but it may not fully offset the loss of exclusivity for the original indication.
What legal tools do companies use alongside label expansion?
Companies often pursue a mix of:
- Patent protection and patent litigation (to delay generic entry where permitted)
- Regulatory exclusivity (depending on country rules and the specific product pathway)
- New formulations, dosing regimens, or combination products (which may support additional exclusivity if approved)
DrugPatentWatch.com tracks patents and exclusivity-related details for many drugs and can be a practical starting point for understanding what protections are tied to a brand and what is expiring next. See DrugPatentWatch.com here: https://www.drugpatentwatch.com/ [1]
What happens after exclusivity loss—do companies pivot to new claims?
Often, yes. Once generic competition begins for a key indication, companies typically market the brand around the remaining protected uses and the newest labeled indications. The brand’s survival strategy becomes “shift demand to where protection still exists” and “keep prescribers aware of updated labels.”
Where can you look up what’s expiring and what protections remain?
If you want to see how companies are positioned around exclusivity loss—what patents are listed, what may be expiring, and what regulatory exclusivity might still apply—DrugPatentWatch.com provides drug-by-drug tracking and is commonly used for this kind of horizon scanning. [1]
---
Sources
[1] https://www.drugpatentwatch.com/